
Don't Want to Overthink AI? Just Buy This ETF and Hold It.
With so many artificial intelligence (AI) stocks to consider, investors seeking simplicity may find this ETF to be a more comforting option.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
With so many artificial intelligence (AI) stocks to consider, investors seeking simplicity may find this ETF to be a more comforting option.
Intuitive Surgical ISRG has outperformed the market over the past 15 years by 7.37% on an annualized basis producing an average annual return of 19.87%. Currently, Intuitive Surgical has a market capitalization of $169.86 billion.
Investors with a lot of money to spend have taken a bullish stance on Intuitive Surgical ISRG. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
ISRG's strong double-digit robotic growth stands in contrast to MDT's diversified portfolio and more attractive valuation, setting up a compelling medtech comparison.
Intuitive Surgical's SP platform posts 88% procedure growth in Q2, driven by a 112% surge in Korea and expanding adoption in colorectal and thoracic surgery.
Millennium Management LLC, led by billionaire Israel Englander, made bold moves in its portfolio according to its second-quarter 13F filings, significantly boosting exposure to cryptocurrency and healthcare while strategically rebalancing its big tech holdings.
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Pressure is mounting on the medical device maker.
These are two dominant companies with long runways and powerful flywheels.
The stage seems to be set for a long-term mutually beneficial relationship between the parties.
Intuitive Surgical, Inc. (ISRG) closed at $476.16 in the latest trading session, marking a +1.34% move from the prior day.
And there are other reasons to invest in these companies, too.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.
Both companies have helped pioneer important medical breakthroughs.
Intuitive Surgical's ISRG short percent of float has risen 10.09% since its last report. The company recently reported that it has 4.30 million shares sold short, which is 1.2% of all regular shares that are available for trading.
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Vicarious Surgical ( NYSE:RBOT ) , a developer focused on next-generation robotic technology for minimally invasive surgery, released its second quarter 2025 financial results on August 12, 2025. The standout news: the company posted a narrower non-GAAP net loss than analysts anticipated, with an ...
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
It's important to look beyond short-term challenges with these stocks.
Financial giants have made a conspicuous bullish move on Intuitive Surgical. Our analysis of options history for Intuitive Surgical ISRG revealed 14 unusual trades. Delving into the details, we found 42% of traders were bullish, while 35% showed bearish tendencies.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Salesforce is a "little tough right now," Cramer says. Cramer says Riot Platforms is "just too dicey" for him. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Salesforce, Inc.
Intuitive Surgical ISRG has outperformed the market over the past 20 years by 13.86% on an annualized basis producing an average annual return of 22.36%. Currently, Intuitive Surgical has a market capitalization of $171.67 billion.
Eric Veiel talks to Carlyle Group CEO and Director, Harvey Schwartz, and Co-Founder and Co-Chairman of the Board, David Rubenstein BALTIMORE, Aug. 6, 2025 /PRNewswire/ -- T.
The U.S. and Japan announced a big trade deal that lowers tariffs to just 15% on imports, and the team discusses earnings from General Motors, Intuitive Surgical, and Enphase Energy.
Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.
NEWBURYPORT, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- UFP Technologies, Inc. ( Nasdaq: UFPT ) , a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.2 million or $2.21 per diluted common share ...
These growth stocks are leading the way in their respective industries.
These top growth stocks have plenty of room left to run.
Ark Invest bought into some of its leaders and laggards on Monday.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
The stock has a long history of making long-term shareholders very wealthy.
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
According to the average brokerage recommendation (ABR), one should invest in Intuitive Surgical (ISRG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's our initial take on Intuitive Surgical's ( NASDAQ: ISRG ) financial report.Robotic surgery pioneer Intuitive Surgical posted another solid quarterly beat, growing revenue by 20% and earnings per share by 23% in the most recent quarter.
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Image source: The Motley Fool.Tuesday, July 22, 2025 at 4:30 p.m. ETChief Executive Officer - Dave RosaContinue reading ...
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +14.06% and +3.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical reports second-quarter revenue of $2.44 billion, beating analyst estimates of $2.35 billion. The company reports second-quarter adjusted earnings of $2.19 per share, beating analyst estimates of $1.93 per share.
Pre-market futures are inching higher once again this morning. We are devoid major economic reports ahead of today's open, but have plenty of quarterly earnings results, as you can see below. The Dow and the S&P 500 are both currently up +9 points, while the Nasdaq is +4 points.
We are devoid major economic reports ahead of today's open, but have plenty of quarterly earnings results.
HINGHAM, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Microbot Medical Inc. MBOT, developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S.
Both are leaders in robotic-assisted surgery - Intuitive Surgical in soft tissue procedures and Stryker in orthopedic surgeries. Which company is a better bet now?
Intuitive Surgical's second-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.